A bill to force the FDA to withdraw mifepristone approval is making headlines again. The science hasn't changed, here's what it actually says.

Montana's abortion providers practice medicine in one of the most publicly contested spaces in health care. Today, we take a moment to see them, thank them, and celebrate their work.

Montana isn't in the middle of a high-profile fight right now. But quiet doesn't mean nothing is happening, and it doesn't mean we stop paying attention.

In January, medication abortion returned to the national spotlight. On January 14, 2026, the Senate Health, Education, Labor, and Pensions Committee held a hearing titled “Protecting Women: Exposing the Dangers of Chemical Abortion Drugs.” The focus was mifepristone, one of the two medications used in medication abortion. At first glance, a Senate hearing in Washington, D.C., may feel far removed from Montana. But when federal lawmakers revisit how a medication is regulated,

A recent House vote to redirect TANF safety net dollars to unregulated pregnancy centers has real consequences. And it's worth understanding exactly what changed and why it matters.